Clinical Trials

Pracinostat

STUDY NO
MEI-008
ESTIMATED ENROLLMENT
25
STATUS
Recruiting
STUDY TITLE
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
ClinicalTrials.gov
STUDY NO
MEI-004
ESTIMATED ENROLLMENT
50
STATUS
Active, Not Recruiting
STUDY TITLE
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Garcia-Manero, et al. ASH Annual Meeting (2016)
STUDY NO
MEI-003
ESTIMATED ENROLLMENT
102
STATUS
Active, Not Recruiting
STUDY TITLE
Phase 2 Study of Pracinostat with Azacitidine in Patients with Previously Untreated Myelodysplastic Syndrome
Garcia-Manero, et al. Cancer (2017)
STUDY NO
2010-0319
ESTIMATED ENROLLMENT
22
STATUS
Completed
STUDY TITLE
Study of SB939 in Subjects with Myelofibrosis
Quintás Crdama, et al. Leukemia Research (2012)
STUDY NO
SB939-2007-002
ESTIMATED ENROLLMENT
38
STATUS
Completed
STUDY TITLE
SB939 in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Razak, et al. British Journal of Cancer (2011)
STUDY NO
SB939-2006-001
ESTIMATED ENROLLMENT
83
STATUS
Completed
STUDY TITLE
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or with Azacitidine
STUDY NO
SB939-2006-001 A
ESTIMATED ENROLLMENT
30
STATUS
Completed
STUDY TITLE
Arm A: Advanced Solid Tumors
Yong, et al. Annals of Oncology (2011)
STUDY NO
SB939-2006-001 B
ESTIMATED ENROLLMENT
44
STATUS
Completed
STUDY TITLE
Arm B: Advanced Hematologic Malignancies
Garcia-Manero, et al. ASH Annual Meeting (2010)
STUDY NO
SB939-2006-001 C
ESTIMATED ENROLLMENT
9
STATUS
Completed
STUDY TITLE
Arm C: Myelodysplastic Syndrome
Quintás Cardama, et al. ASH Annual Meeting (2012)

ME-401

STUDY NO
ME-401-002
ESTIMATED ENROLLMENT
84
STATUS
Recruiting
STUDY TITLE
Study of ME-401 in Subjects With Relapsed/Refractory CLL/SLL or FL
ClinicalTrials.gov
STUDY NO
PWT-143
ESTIMATED ENROLLMENT
35
STATUS
Active, Not Recruiting
STUDY TITLE
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT143
Moreno, et al. AACR Annual Meeting (2016)

ME-344

STUDY NO
CNIO-BR-009
ESTIMATED ENROLLMENT
40
STATUS
Recruiting
STUDY TITLE
ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism
ClinicalTrials.gov
STUDY NO
ME-344-001
ESTIMATED ENROLLMENT
30
STATUS
Completed
STUDY TITLE
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Bendell, et al. Cancer (2015)